Half-Year 2022 Financial and Clinical Trials Update

Immunology franchise Actemra COVID-19 sales declining and first Esbriet generic competition CHFM YoY CER growth 2,500 +7% +2% +1% 2,000 -12% 1,500 1,000 500 Immunology Q2 update Gazyva: Ph III (INShore) in PNS initiated Actemra (-23%) • . Strong decline of COVID-19 driven sales • Remains leading RA monotherapy in EU-5 • Shift from IV to SC; SC sales accounting for >65% Xolair (+13%) • Remains the leader in biologics asthma market Actemra IV Xolair Q222 • Continued growth in CSU Esbriet (-21%) • US: Generic competition Outlook 2022 0 Q2 19 Q2 20 Q2 21 Rituxan/MabThera (RA) Actemra SC CellCept Esbriet Pulmozyme Other Roche . • Actemra: Limited COVID-19 sales due to fewer hospitalizations 27 CER=Constant Exchange Rates; PNS-Pediatric Nephrotic Syndrome; RA-rheumatoid arthritis; IV-intravenous; SC=subcutaneous; CSU-chronic spontaneous urticaria

View entire presentation